Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
Business Wire•08/10/2026•07:30 ET
0
Key Highlights
- ➤Agenus receives Armenia’s first marketing authorizations for BOT+BAL in MSS metastatic colorectal cancer
- ➤Approvals cover previously treated adults without active liver metastases
- ➤Authorizations are conditional, valid one year, and renewable with annual clinical updates
- ➤Agenus will evaluate approvals in other Eurasian Economic Union member countries
Expert Statements
Garo H. Armen, Chairman and Chief Executive Officer of Agenus
“Armenia is the first country in the world to grant marketing approval for BOT+BAL”
Garo H. Armen, Chairman and Chief Executive Officer of Agenus
“The evidence behind this decision has been published in peer-reviewed journals and presented at major cancer conferences, and it has consistently pointed to clinical benefit for patients with metastatic colorectal cancer.”
Garo H. Armen, Chairman and Chief Executive Officer of Agenus
“We thank Armenia’s health authorities for the depth and care of their review.”
Garo H. Armen, Chairman and Chief Executive Officer of Agenus
“Patients who have exhausted standard treatments now have a new option, and we are proud to bring it to them.”
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
* Botvymo(®) (botensilimab) and Evamplix(®) (balstilimab) receive separate approvals for use in combination
Get started
Create a free account to read the full story.